Pfizer begins testing oral antiviral drug in U.S. to treat COVID-19

Pfizer, the first company to receive FDA emergency approval for a COVID-19 vaccine, is now working on an oral antiviral medication to treat the disease caused by the virus. File Photo by Debbie Hill/UPI

March 23 (UPI) — Pfizer announced Tuesday it’s beginning a U.S.-based early-stage study of an oral antiviral drug to treat COVID-19.

The antiviral candidate, called PF-07321332, is what’s known as a protease inhibitor and could be prescribed to patients showing the first signs of a COVID-19 infection. The pharmaceutical company said the antiviral clinical candidate might be able to address future coronavirus threats, as well.

“Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus,” Mikael Dolsten, chief scientific officer and president of worldwide research, development and medical at Pfizer, said in a statement.

“Given the way that [the virus] is mutating and the continued global impact of COVID-19, it appears likely that it will be critical to have access to therapeutic options both now and beyond the pandemic.”

The Phase 1 trial will involve health adults to evaluate safety and tolerability of the drug.

Protease inhibitors work by binding to a viral enzyme, preventing a virus from replicating inside a cell. Such therapeutics have been used to treat HIV and hepatitis C.

The Food and Drug Administration has already granted emergency use authorization to the antiviral remdesivir to treat COVID-19. It was developed to treat the Ebola virus.

Former President Donald Trump was given multiple doses of the drug after he was hospitalized in October. The World Health Organization has since recommended against using remdesivir in COVID-19 patients because it said it’s had “no meaningful effect on mortality” or other outcomes.

Meanwhile, the results of a Phase 2 trial of an experimental hepatitis D antiviral drug showed that it appears to speed recovery times for non-hospitalized COVID-19 patients. Those given peginterferon-lambda were four times as likely to have cleared the COVID-19 infection within seven days compared to those who received a placebo.

Pfizer, in its partnership with BioNTech, received the FDA’s first emergency use authorization for a vaccine to prevent COVID-19 in late 2020.


Please enter your comment!
Please enter your name here